Last reviewed · How we verify
CJ-30001/CJ-30002
CJ-30001/CJ-30002 is a dual GLP-1/GCG receptor agonist that activates both glucagon-like peptide-1 and glucagon receptors to improve glycemic control and promote weight loss.
CJ-30001/CJ-30002 is a dual GLP-1/GCG receptor agonist that activates both glucagon-like peptide-1 and glucagon receptors to improve glycemic control and promote weight loss. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | CJ-30001/CJ-30002 |
|---|---|
| Sponsor | HK inno.N Corporation |
| Drug class | Dual GLP-1/GCG receptor agonist |
| Target | GLP-1 receptor, Glucagon receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology/Diabetes |
| Phase | Phase 3 |
Mechanism of action
By simultaneously activating GLP-1 and glucagon receptors, this dual agonist enhances insulin secretion, reduces glucagon secretion in a glucose-dependent manner, and increases energy expenditure. This dual mechanism is designed to provide superior glycemic control and greater weight reduction compared to GLP-1 monotherapy in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Gastrointestinal disorders
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CJ-30001/CJ-30002 CI brief — competitive landscape report
- CJ-30001/CJ-30002 updates RSS · CI watch RSS
- HK inno.N Corporation portfolio CI